<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00911898</url>
  </required_header>
  <id_info>
    <org_study_id>MM-111-01-100</org_study_id>
    <nct_id>NCT00911898</nct_id>
  </id_info>
  <brief_title>A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers</brief_title>
  <acronym>Monotherapy</acronym>
  <official_title>A Phase 1 and Pharmacologic Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merrimack Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merrimack Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label Phase 1 trial of MM-111.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1: Patients with any solid tumor type may be enrolled to evaluate the safety and
      tolerability of MM-111.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) or Maximum Feasible Dose</measure>
    <time_frame>28 days</time_frame>
    <description>The Maximum Tolerated Dose (MTD) was defined as the highest dose level in which a DLT is experienced by fewer than two patients in a cohort of 3 - 6 patients. If a DLT is observed in at least two patients in a cohort of 3 - 6 patients, the MTD will be determined to have been exceeded and an additional three patients (up to a total of six) are to be treated at the next lower dose level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Determine the Clinical Activity of MM-111 in Patients Based on Objective Response Rate (ORR), Duration of Response (DoR), Progression Free Survival (PFS), and 16 &amp; 24-week Clinical Benefit Rate (CBR)</measure>
    <time_frame>December 2011</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Explore the Role Functional Imagining (FDG-PET CT Scan), as a Predictor of Clinical Activity</measure>
    <time_frame>December 2011</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Her2 Amplified Solid Tumors</condition>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>MM-111</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MM-111</intervention_name>
    <description>For Phase 1: Dose-escalation cohorts, drug is administered weekly via IV</description>
    <arm_group_label>MM-111</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed advanced cancer that is:

               -  HER2 amplified (IHC 2+ or greater) based on archived tumor evaluation

               -  Heregulin positive based on a study required fresh biopsy sample performed at
                  screening and confirmed by central laboratory

          -  Patients must have blocks of archived formalin-fixed, paraffin-embedded tumor tissue
             available for sectioning and immunohistochemical staining

          -  Patient's cancer must have recurred or progressed following standard therapy, have not
             responded to standard therapy, or for which no standard therapy exists.

          -  Patients must be &gt;= 18 years of age

          -  Patients or their legal representatives must be able to understand and sign an
             informed consent

          -  Patients may have measurable or non-measurable tumor(s)

          -  Patients should have ECOG Performance Score (PS) 0 or 1

          -  Patients must have adequate bone marrow reserves as evidenced by:

               -  Absolute neutrophil count (ANC) &gt;= 1,500/uL and

               -  Platelet count &gt;= 100,000/uL

               -  Hemoglobin &gt;= 9 g/dL

          -  Patients must have tumor tissue amenable to biopsy

          -  Patients must be willing to undergo biopsy prior to treatment to MM-111

        Exclusion Criteria:

          -  Patients for whom potentially curative antineoplastic therapy is available

          -  Patients who are pregnant or lactating

          -  Patients with an active infection or with an unexplained fever greater than 38.5 C
             during screening visits or on the first scheduled day of dosing. (At the discretion of
             the investigator, patients with tumor fever may be enrolled)

          -  Patients with untreated and/or symptomatic primary or metastatic CNS malignancies
             (patients with CNS metastases who have undergone surgery or radiotherapy, whose
             disease is stable, and who have been on a stable dose of corticosteroids for at least
             2 weeks prior to the first scheduled day of dosing will be eligible for the trial

          -  Patients with known hypersensitivity to any of the components of MM-111 or who have
             had hypersensitivity reactions to fully human monoclonal antibodies (patients with a
             history of hypersensitivity to trastuzumab, a humanized antibody, are not excluded)

          -  Patients with known HIV, hepatitis B or C (if patients have previously been treated
             for C and have undetectable viral loads, they can be considered eligible for the
             trial)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muralidhar Beeram, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The START Center for Cancer Care</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern California Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University (IUPUI)</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46268</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2009</study_first_submitted>
  <study_first_submitted_qc>June 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2009</study_first_posted>
  <results_first_submitted>February 28, 2014</results_first_submitted>
  <results_first_submitted_qc>September 11, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 15, 2014</results_first_posted>
  <last_update_submitted>December 30, 2014</last_update_submitted>
  <last_update_submitted_qc>December 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Her2 amplified solid tumors</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Her3/ErbB3</keyword>
  <keyword>Bispecific Antibody</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MM-111</title>
          <description>MM-111: For Phase 1: Dose-escalation cohorts, drug is administered weekly via IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MM-111</title>
          <description>MM-111: For Phase 1: Dose-escalation cohorts, drug is administered weekly via IV</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.0" lower_limit="30" upper_limit="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>To Determine the Clinical Activity of MM-111 in Patients Based on Objective Response Rate (ORR), Duration of Response (DoR), Progression Free Survival (PFS), and 16 &amp; 24-week Clinical Benefit Rate (CBR)</title>
        <time_frame>December 2011</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Explore the Role Functional Imagining (FDG-PET CT Scan), as a Predictor of Clinical Activity</title>
        <time_frame>December 2011</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD) or Maximum Feasible Dose</title>
        <description>The Maximum Tolerated Dose (MTD) was defined as the highest dose level in which a DLT is experienced by fewer than two patients in a cohort of 3 - 6 patients. If a DLT is observed in at least two patients in a cohort of 3 – 6 patients, the MTD will be determined to have been exceeded and an additional three patients (up to a total of six) are to be treated at the next lower dose level.</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MM-111</title>
            <description>All participants</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD) or Maximum Feasible Dose</title>
          <description>The Maximum Tolerated Dose (MTD) was defined as the highest dose level in which a DLT is experienced by fewer than two patients in a cohort of 3 - 6 patients. If a DLT is observed in at least two patients in a cohort of 3 – 6 patients, the MTD will be determined to have been exceeded and an additional three patients (up to a total of six) are to be treated at the next lower dose level.</description>
          <units>mg/kg</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="4.4" upper_limit="8.0">MTD was not attained as no patients experienced a dose limiting toxicity.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MM-111</title>
          <description>MM-111: For Phase 1: Dose-escalation cohorts, drug is administered weekly via IV</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease Progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute viral myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Peural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Muralibhar Beeram</name_or_title>
      <organization>South Texas Accelerated Research Therapeutics</organization>
      <phone>210-593-5921</phone>
      <email>murali.beeram@stoh.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

